460 reports of this reaction
3.8% of all IVABRADINE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for IVABRADINE, manufactured by Amgen Inc. There are 460 FDA adverse event reports linking IVABRADINE to DYSPNOEA. This represents approximately 3.8% of all 12,129 adverse event reports for this drug.
Patients taking IVABRADINE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among IVABRADINE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for IVABRADINE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 460 FDA reports for IVABRADINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.8% of all adverse event reports for IVABRADINE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking IVABRADINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.